-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
-
Media ReleaseNovartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program
-
Media ReleaseNovartis commits to addressing racial disparities in breast cancer screening, treatment and care
-
Media ReleaseNovartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseNovartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media ReleaseNovartis and Amgen partner with Karamo Brown to support and empower people living with migraine
-
Media ReleaseNovartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps